From JCO: Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma

"Immune checkpoint blockade with anti-CTLA-4 and anti-PD-1 has revolutionized the treatment of a variety of malignancies. Despite recent advances, many outstanding questions, such as the definitions of the optimal dose, schedule, combinations, and duration of therapy; the development of robust predictors of likely benefit; toxicity; and the development of better ways to manage toxicities, still need to be addressed. These questions can only be explored through prospective clinical trials and broad collaborative research."

Vi3C intends to perform research on optimal dose, schedule and duration of immunotherapy agents.